en · de · es · fr · pt
lab-handbook.peptides7250.com › Topic › Handling, Stability And Analysis — Questions and Answers

Handling, Stability And Analysis — Questions and Answers

By Editorial Desk · published 2025-08-14 · last reviewed 2025-10-03 · Topic

The short version of CJC-1295 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-10-03 and is reviewed periodically as new material appears.

Handling, Stability and Analysis

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Identity and Naming History

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Appearance as powderWhite to off-white solidMinor batch-to-batch variation is normal
Solubility classSoluble in water and aqueous buffersDissolution can be slowed by aggregates
Typical storage temperatureMinus 20 degrees Celsius or belowProtected from light and moisture
Storage after reconstitution2 to 8 degrees Celsius, short termLonger holding requires freezing
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity and identity confirmation

CJC-1295 Structure And Mechanism

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Related pages on this site

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Further detail

=== Pulmonary function test === The forced vital capacity may be monitored at intervals to detect increasing muscular weakness. Acutely, negative inspiratory force may be used to determine adequacy of ventilation; it is performed on those individuals with MG.

== Further reading == "Biographical Entry: Dr. Martin Litchfield West"[link removed], Debrett's People of Today, Debrett's Limited, 18–20 Hill Rise, Richmond, Surrey TW10 6UA United Kingdom. Fries, Almut (2015). "Martin Litchfield West (1937–2015)". Studia Metrica et Poetica. 2 (2): 152–158. doi:10.12697/smp.2015.2.2.12. ISSN 2346-6901. Lightfoot, J. L. (September 2017). "Martin Litchfield West" (PDF). Proceedings of the American Philosophical Society. 161 (3): 285–292.

=== Function in plants and cyanobacteria === Vitamin K1 is an important chemical in green plants (including land plants and green algae) and some species of cyanobacteria, where it functions as an electron acceptor transferring one electron in photosystem I during photosynthesis. For this reason, vitamin K1 is found in large quantities in the photosynthetic tissues of plants (green leaves, and dark green leafy vegetables such as romaine lettuce, kale, and spinach), but it occurs in far smaller quantities in other plant tissues. Detection of VKORC1 homologues active on the K1-epioxide suggest that K1 may have a non-redox function in these organisms. In plants but not cyanobacteria, knockout of this gene show growth restriction similar to mutants lacking the ability to produce K1.

In 1947, Raleigh citizens adopted a council–manager form of government, which is still the city's current form of government. The Dorton Arena, a 7,610-seat multi-purpose arena designed by Matthew Nowicki, was opened in 1952 on the grounds of the North Carolina State Fair. It was listed in the National Register of Historic Places in 1973.

=== CRF1 === Agonists: Cortagine Corticorelin Corticotropin-releasing hormone Sauvagine Stressin I Urocortin Antagonists: Antalarmin Astressin-B CP-154,526 Emicerfont Hypericin LWH-234 NBI-27914 NBI-74788 Pexacerfont R-121919 TS-041 Verucerfont

Sources: en.wikipedia.org

Supporting material

=== Long-term === Finasteride may cause persistent adverse sexual, neurological, and physical effects in a subset of men. A 2019 systematic review surveyed the literature on the reversibility of finasteride's side effects. It identified three studies that demonstrated full reversibility of side effects and eleven that described patients with irreversible adverse events. A separate 2017 retrospective review of nearly 12,000 patients found 1.4% developed persistent (lasting at least 90 days after stopping Finasteride) ED, with this dropping to 0.8% for 16-42 year olds.

==== Oklahoma restaurant closures ==== In 2015, the Oklahoma Tax Commission shuttered 15 Church's Chicken restaurants owned by the Reciprocity Restaurant Group LLC, for not paying more than $400,000 in sales taxes to the state of Oklahoma.

== Honours and awards == Commonwealth Scholar at Trinity College, Cambridge, 1960-1963 Powell Prize for English Verse, Trinity College, 1961 Vidya Jyothi from the President of Sri Lanka, 1992 Honorary DLitt, Sōka University (Japan), 1996 Doctor of Science (honoris causa), University of Ruhuna, Sri Lanka, 2004 Visiting By-Fellowship, visiting scholar, Churchill College, Cambridge, England 2015/16 Ada Derana Sri Lankan of the Year 2017 - Global Scientist Wickramasinghe was appointed Member of the Order of the British Empire (MBE) in the 2022 New Year Honours for services to science, astronomy and astrobiology.

=== Appeal === In January 2024, Letby applied to the Court of Appeal for permission to challenge her convictions, but this was refused by a single judge. She renewed her application, and at a three‑day hearing in April 2024 her legal team advanced four grounds of appeal relating to the trial judge's rulings. In May 2024, a panel comprising Dame Victoria Sharp, Lord Justice Holroyde and Mrs Justice Lambert refused permission to appeal. As part of the appeal, Letby's counsel, Ben Myers, again challenged the admission of evidence from paediatrician Evans, arguing that it should have been excluded on the basis that Evans had been "dogmatic and biased". The appeal judges rejected this, finding that Evans did not lack impartiality, was suitably qualified to give expert evidence, and that it was for the jury to assess its weight. A second ground of appeal concerned the medical evidence relating to alleged fatal air injections, which the defence described as "very weak". A third ground argued that the trial judge had erred in directing the jury that they could convict even if they were uncertain about the precise method used in each case. The final ground alleged that the judge had failed to investigate a question of juror impartiality. All four grounds were dismissed, with the Court concluding in its written judgement that the trial had been "thoughtful, fair, comprehensive and correct" and that none of the challenges raised by the defence were "arguable".

Sources: en.wikipedia.org

Frequently asked questions

Why is mass spectrometry used alongside chromatography?

Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.

What drives degradation of the peptide in solution?

Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.

Is a purity percentage directly comparable between suppliers?

Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network